Description
Pfizer’s Fightback Against Eli Lilly & Novo Nordisk: Who Gets OUTPLAYED in the Obesity Arms Race?
Pfizer just released mid-stage data from its Metsera-acquired obesity drug showing 12.3% weight loss at 28 weeks with monthly dosing. It’s the company’s first real swing at the obesity market after acquiring Metsera for $10 billion to diversify beyond fading COVID revenues. The headline efficacy looks decent but not industry-leading — and that’s exactly what the market is focused on. What matters more is how the timeline, design, and dosing frequency compare with entrenched rivals like Lilly and Novo, and where Pfizer may still carve out a lane.
